ATE512974T1 - Genetisch manipuliertes p30 antigen, verbesserter antigen-cocktail und ihre verwendung - Google Patents

Genetisch manipuliertes p30 antigen, verbesserter antigen-cocktail und ihre verwendung

Info

Publication number
ATE512974T1
ATE512974T1 AT08171374T AT08171374T ATE512974T1 AT E512974 T1 ATE512974 T1 AT E512974T1 AT 08171374 T AT08171374 T AT 08171374T AT 08171374 T AT08171374 T AT 08171374T AT E512974 T1 ATE512974 T1 AT E512974T1
Authority
AT
Austria
Prior art keywords
antigen
genetically engineered
antigens
combination
cocktail
Prior art date
Application number
AT08171374T
Other languages
English (en)
Inventor
Gregory T Maine
Chandu B Patel
Sanford R Ginsburg
Timothy R Bliese
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Application granted granted Critical
Publication of ATE512974T1 publication Critical patent/ATE512974T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/45—Toxoplasma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56905—Protozoa
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/44—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from protozoa
    • G01N2333/45—Toxoplasma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT08171374T 2002-10-02 2003-10-02 Genetisch manipuliertes p30 antigen, verbesserter antigen-cocktail und ihre verwendung ATE512974T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/263,153 US7094879B2 (en) 2002-10-02 2002-10-02 Genetically engineered P30 antigen, improved antigen cocktail, and uses thereof

Publications (1)

Publication Number Publication Date
ATE512974T1 true ATE512974T1 (de) 2011-07-15

Family

ID=32041949

Family Applications (2)

Application Number Title Priority Date Filing Date
AT08171374T ATE512974T1 (de) 2002-10-02 2003-10-02 Genetisch manipuliertes p30 antigen, verbesserter antigen-cocktail und ihre verwendung
AT03781303T ATE430757T1 (de) 2002-10-02 2003-10-02 Gentechnisch hergestelltes p30-antigen, verbesserter antigen-cocktail und verwendungen davon

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT03781303T ATE430757T1 (de) 2002-10-02 2003-10-02 Gentechnisch hergestelltes p30-antigen, verbesserter antigen-cocktail und verwendungen davon

Country Status (8)

Country Link
US (3) US7094879B2 (de)
EP (2) EP2067783B1 (de)
JP (1) JP4602084B2 (de)
AT (2) ATE512974T1 (de)
CA (1) CA2501040C (de)
DE (1) DE60327544D1 (de)
ES (2) ES2325578T3 (de)
WO (1) WO2004031358A2 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7094879B2 (en) 2002-10-02 2006-08-22 Abbott Laboratories Genetically engineered P30 antigen, improved antigen cocktail, and uses thereof
WO2006094665A1 (en) * 2005-03-08 2006-09-14 Kenton Srl Chimeric recombinant antigens of toxoplasma gondii
US7432046B2 (en) * 2005-11-02 2008-10-07 Abbott Laboratories Methods for the determination of antibody IgG avidity
KR100803055B1 (ko) * 2006-11-03 2008-02-18 한국과학기술원 구면베어링 조립체의 제조장치 및 그 제조방법
CN102288768A (zh) * 2011-09-19 2011-12-21 厦门市湖里区妇幼保健院 弓形虫IgG抗体免疫印迹试剂盒及其制备方法
CN102360012A (zh) * 2011-09-19 2012-02-22 厦门大学附属中山医院 弓形虫IgG抗体与总抗体联合检测试剂条及其制备方法
CN108165569A (zh) * 2017-11-10 2018-06-15 江苏省血吸虫病防治研究所 一种快速检测弓形虫的重组蛋白及其制备方法和应用
CN120795059A (zh) 2018-08-27 2025-10-17 瑞泽恩制药公司 拉曼光谱在下游纯化中的应用
US12012433B1 (en) * 2020-02-27 2024-06-18 Integrated Dna Technologies Inc. Expression and purification of Cas enzymes
CA3176675A1 (en) 2020-05-01 2021-11-04 Integrated Dna Technologies, Inc. Lachnospiraceae sp. cas12a mutants with enhanced cleavage activity at non-canonical tttt protospacer adjacent motifs

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57501692A (de) 1980-09-24 1982-09-16
DE3940598A1 (de) 1989-12-08 1991-06-13 Behringwerke Ag Toxoplasma gondii-antigene, ihre herstellung und ihre verwendung
US4582788A (en) 1982-01-22 1986-04-15 Cetus Corporation HLA typing method and cDNA probes used therein
ATE53862T1 (de) 1982-01-22 1990-06-15 Cetus Corp Verfahren zur charakterisierung von hla und die darin benutzten cdns-testmittel.
US4683194A (en) 1984-05-29 1987-07-28 Cetus Corporation Method for detection of polymorphic restriction sites and nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
CA1284931C (en) 1986-03-13 1991-06-18 Henry A. Erlich Process for detecting specific nucleotide variations and genetic polymorphisms present in nucleic acids
CA1338457C (en) 1986-08-22 1996-07-16 Henry A. Erlich Purified thermostable enzyme
US5643758A (en) 1987-03-10 1997-07-01 New England Biolabs, Inc. Production and purification of a protein fused to a binding protein
US5231020A (en) 1989-03-30 1993-07-27 Dna Plant Technology Corporation Genetic engineering of novel plant phenotypes
US5912120A (en) 1992-04-09 1999-06-15 The United States Of America As Represented By The Department Of Health And Human Services, Cloning, expression and diagnosis of human cytochrome P450 2C19: the principal determinant of s-mephenytoin metabolism
FR2722508B1 (fr) * 1994-07-13 1996-10-04 Transgene Sa Cassette d'expression d'une proteine p30 de toxoplasma gondii
US6183952B1 (en) 1996-08-19 2001-02-06 Abbott Laboratories Reagents and methods useful for detecting diseases of the breast
CA2333598C (en) * 1998-05-28 2009-10-13 Abbott Laboratories Toxoplasma gondii antigens, p35, and uses thereof
US6329157B1 (en) * 1998-05-28 2001-12-11 Abbott Laboratories Antigen cocktails and uses thereof
AU4510299A (en) * 1998-06-12 2000-01-05 Smithkline Beecham Biologicals (Sa) Recombinant production of toxoplasma sag1 antigen
US6395472B1 (en) 1999-02-05 2002-05-28 Abbott Laboratories Methods of utilizing the TT virus
US7094879B2 (en) 2002-10-02 2006-08-22 Abbott Laboratories Genetically engineered P30 antigen, improved antigen cocktail, and uses thereof

Also Published As

Publication number Publication date
ES2366306T3 (es) 2011-10-19
US20040067239A1 (en) 2004-04-08
JP2006501826A (ja) 2006-01-19
EP1556404B1 (de) 2009-05-06
EP1556404A4 (de) 2006-07-26
US7824908B2 (en) 2010-11-02
US7314924B2 (en) 2008-01-01
ATE430757T1 (de) 2009-05-15
JP4602084B2 (ja) 2010-12-22
EP2067783B1 (de) 2011-06-15
CA2501040C (en) 2015-04-21
US7094879B2 (en) 2006-08-22
EP1556404A2 (de) 2005-07-27
CA2501040A1 (en) 2004-04-15
WO2004031358A2 (en) 2004-04-15
ES2325578T3 (es) 2009-09-09
EP2067783A1 (de) 2009-06-10
US20060105451A1 (en) 2006-05-18
US20080160606A1 (en) 2008-07-03
WO2004031358A3 (en) 2005-06-02
DE60327544D1 (de) 2009-06-18

Similar Documents

Publication Publication Date Title
DK1584685T3 (da) Tumorassocieret antigenderivater fra Mage-familien, anvendt til fremstilling af fusionsproteiner med T-hjælper epitoper og sammensætninger til vaccination
DK0970126T3 (da) Hidtil ukendt fremgangsmåde til fremstillingen af anti-humant antigen-receptorer og anvendelser deraf
ATE554107T1 (de) Als therapeutika geeignete monovalente antikörperfragmente
DK1565489T3 (da) Internaliserende antistoffer specifikke for RAAG10-celleoverflademålet
MXPA06010673A (es) Reduccion del riesgo de anticuerpos humanos anti-humano a traves de manipulacion del gen v.
DE60142689D1 (de) Verwendung prokariotischer pest-ähnlicher peptide zur verstärkung der immunogenität von antigenen
WO2005047860A3 (en) Antibodies to alpha-synuclein
BR0315161A (pt) Anticorpo isolado, polinicleotìdeo isolado, vetor, célula hospedeira, método de produzir um anticorpo, e, composição
NZ594466A (en) Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies
LU92710I2 (fr) Ramucirumab et ses dérivés pharmaceutiquement acceptables (cyramza)
DE69431404D1 (de) Verfahren zur mikroverkapselung von antigenen und verwendung der zusammensetzungen als impfstoffe
ATE481108T1 (de) Verwendung von bioadhaesiven und adjuvantien für die mukosale anwendung von antigenen
ATE459706T1 (de) Monoklonales antikörper gegen das hcv kernantigen
ATE517340T1 (de) Sätze gegen kurze epitope gerichteter digitaler antikörper sowie diese verwendende verfahren
ATE530572T1 (de) Antigen-cocktails, p35 und verwendungen dafür
DE60042066D1 (de) Chimärische dr4 antikörper und ihre verwendung
ATE430757T1 (de) Gentechnisch hergestelltes p30-antigen, verbesserter antigen-cocktail und verwendungen davon
WO2004016586A3 (en) Compositions and methods related to flavivirus envelope protein domain iii antigens
WO2004060295A3 (en) Methods of inducing and maintaining immune tolerance
ATE463515T1 (de) Chimaere rekombinante antigene von toxoplasma gondii
EP1412538A4 (de) Verfahren zum gleichzeitigen nachweis von hcv-antigenen und hcv-antikörpern
ATE477274T1 (de) Gegen clostridium difficile gerichtete antikörper
DE69504959D1 (de) Humanisierte monoklonale antikörper gegen humanes interleukin - 4
DE60324003D1 (en) Hcv-test
WO2003040341A3 (en) Anti-hepatitis a virus antibodies

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties